✦ LIBER ✦

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

✍ Scribed by Leena Gandhi; Matthew W. Harding; Marcus Neubauer; Corey J. Langer; Melvin Moore; Helen J. Ross; Bruce E. Johnson; Thomas J. Lynch

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 112 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22492

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of cyclophosph

Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma

✍ Shane C. White; Paul Lorigan; Mark R. Middleton; Heather Anderson; Juan Valle; Y 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

A Phase I–II study of sequential adminis

A Phase I–II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma

✍ Tony S. K. Mok; Herman Wong; Benny Zee; Kwok Hung Yu; Thomas W. T. Leung; Tak Wa 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan (9‐dimethylaminomethyl‐10‐hydroxycampthothecin) is a new topoisomerase I inhibitor with promising efficacy in the treatment of patients with small cell lung carcinoma (SCLC). Combination with a topoisomerase II inhibitor may potentate the therapeutic effect of t

Paclitaxel, carboplatin, and topotecan i

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma : A Phase II trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Lisa H. Morrissey; Daniel C. Scullin Jr.; Gerry Ann Houston; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the feasibility, toxicity, and efficacy of a novel three‐drug regimen containing paclitaxel, carboplatin, and topotecan followed by oral etoposide in the first‐line treatment of patients with small cell lung carcinoma. ## METHO

A randomized phase II trial of amonafide

A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group

✍ Dean H. Gesme Jr.; James R. Jett; Dennis D. Schreffler; John Q. Su; James A. Mai 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB 👁 2 views

Efficacy and toxicity of 2 schedules of

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma : A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA)

✍ Vincent Ribrag; Christian Gisselbrecht; Corinne Haioun; Gilles Salles; Jean-Bapt 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

Alternating chemotherapy with etoposide

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma : A Phase II trial of the North Central Cancer Treatment Group

✍ James R. Jett; Alan K. Hatfield; Shauna Hillman; Michael D. Bauman; James A. Mai 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive‐stage small cell lung carcinoma (SCLC). ## METHODS Patients with histologically proven, extensive‐stage SCLC, with a perfor